Illustrative image – not actual.
AstraZeneca Pharma India (AZPIL), a subsidiary of AstraZeneca UK, is planning to sell its production facility in Bengaluru, Karnataka. As a part of an ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore in due course.
The biopharmaceutical company will position the manufacturing site for sale in a fully operational manner and start looking for a buyer who can serve as a contract manufacturing organisation (CMO) for its products, which is currently manufactured or packaged at the site, subject to receipt of necessary statutory approvals.
AZPIL's Bengaluru facility is one of the nine global sites, which supports the design and conduct of clinical trials, monitoring of safety and efficacy as well as other regulatory management required during a product's lifecycle.
Furthermore, the firm is committed to advancing access to innovative medicines in India with an aim to be pioneers in science, lead in specialist disease areas, and transform patient outcomes.
